First patient enrolled in the AMLM22-CADENCE trial with Mendus’ product vididencel

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that the first patient has been enrolled in the AMLM22-CADENCE trial, which studies Mendus’ lead product vididencel as a novel maintenance therapy in acute myeloid leukemia (AML). In this multi-center, randomized controlled Phase 2 trial, the Australasian Leukaemia and Lymphoma Group (ALLG) is studying vididencel as a novel AML maintenance treatment in combination with oral azacitidine (AZA), currently the only approved AML maintenance drug. In the trial, patients in first complete remission following intensive induction chemotherapy receive standard treatment with AZA or the combination of AZA + vididencel. Vididencel is administered as 4 biweekly intradermal injections, followed by 3 booster injections up to 6 months after start of treatment. The first stage of the AMLM22-CADENCE trial will randomize 40 patients and in the second stage, efficacy of the combination will be assessed in an additional 100 patients. This trial will provide initial safety data on vididencel as add-on to current standard of care and contributes to the further expansion of the regulatory dossier. For more information, please contact: Erik Manting Chief Executive Officer E-mail: [email protected] About Mendus AB (publ) Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/ Attachments First patient enrolled in the AMLM22-CADENCE trial with Mendus’ product vididencel

The release as fetched from its publisher. mendus.com ↗